Phase 1b Study of HSP90 Inhibitor, AT13387 in Combination With Paclitaxel in Patients With Advanced, Triple Negative Breast Cancer
Phase of Trial: Phase I
Latest Information Update: 23 Oct 2017
At a glance
- Drugs Onalespib (Primary) ; Paclitaxel (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- 01 Aug 2017 Status changed from suspended to recruiting.
- 20 Jul 2017 Status changed from recruiting to suspended.
- 10 Jun 2017 Biomarkers information updated